ABVC BioPharma
ABVC
9 hedge funds and large institutions have $79.8K invested in ABVC BioPharma in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
1.77% more ownership
Funds ownership: 0.18% → 1.94% (+1.8%)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
74% less capital invested
Capital invested by funds: $304K → $79.8K (-$224K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$49K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$37.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.86K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$49.4K |
| 2 |
Two Sigma Investments
New York
|
-$11.5K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$9.57K |
| 4 |
BlackRock
New York
|
-$3.02K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $21K | +$49K | +20,265 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $20.3K | +$13.4K | +5,552 | +40% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $19.1K | -$49.4K | -20,430 | -53% |
|
|
4
Citadel Advisors
Miami,
Florida
| $16.2K | +$37.7K | +15,591 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3.1K | +$3.86K | +1,597 | +115% |
|
|
SAG
6
Spotlight Asset Group
Oakbrook Terrace,
Illinois
| $104 | – | – | – |
|
|
7
Wells Fargo
San Francisco,
California
| $19 | +$12 | +5 | +38% |
|
8
JP Morgan Chase
New York
| $2 | +$5 | +2 | New |
|
|
9
Two Sigma Investments
New York
| – | -$11.5K | -2,210 | Closed |
|
|
10
Northern Trust
Chicago,
Illinois
| – | -$9.57K | -1,842 | Closed |
|
|
11
BlackRock
New York
| – | -$3.02K | -581 | Closed |
|
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2 | -1 | -3% |
|
ABVC Hedge Fund Activity: Q3 2023 in Review
9 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q3 2023, worth a combined $79.8K — down 74% from $304K a quarter earlier.
Fund positioning in ABVC was balanced in Q3 2023: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $49K. The largest seller was Vanguard Group, cutting an estimated $49.4K.
- 9 institutional investors held ABVC BioPharma (ABVC) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $79.8K of ABVC BioPharma stock for Q3 2023, down 74% quarter-over-quarter.
- 3 funds opened new ABVC BioPharma positions in Q3 2023 and 3 closed out, a net change of 0 holders.
- The largest ABVC BioPharma buyer in Q3 2023 was Virtu Financial, an estimated $49K added.
- The largest ABVC BioPharma seller in Q3 2023 was Vanguard Group, an estimated $49.4K sold.
Based on aggregated 13F filings for Q3 2023.